Obseva (NASDAQ:OBSV) Earns Buy Rating from Wedbush

Wedbush reissued their buy rating on shares of Obseva (NASDAQ:OBSV) in a research note issued to investors on Tuesday, AnalystRatings.com reports. They currently have a $36.00 price target on the stock.

Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Obseva from a strong sell rating to a sell rating in a research report on Wednesday, October 30th. Zacks Investment Research upgraded shares of Obseva from a sell rating to a hold rating in a research report on Saturday, November 9th. Credit Suisse Group downgraded shares of Obseva from an outperform rating to a neutral rating and reduced their price target for the stock from $16.00 to $4.00 in a research report on Friday, November 8th. Royal Bank of Canada upped their price target on shares of Obseva from $18.00 to $19.00 and gave the stock an outperform rating in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a buy rating and set a $40.00 price target on shares of Obseva in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $24.75.

Shares of NASDAQ:OBSV traded down $0.36 on Tuesday, hitting $3.92. The stock had a trading volume of 982,326 shares, compared to its average volume of 752,357. Obseva has a twelve month low of $2.37 and a twelve month high of $14.59. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.65 and a current ratio of 3.65. The firm’s 50 day moving average price is $3.71 and its 200-day moving average price is $6.88. The company has a market capitalization of $194.65 million, a price-to-earnings ratio of -1.58 and a beta of 0.50.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.19. As a group, sell-side analysts predict that Obseva will post -2.68 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley lifted its position in Obseva by 358.6% during the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after buying an additional 2,424 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Obseva by 263.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after purchasing an additional 2,372 shares during the last quarter. Wedbush Securities Inc. raised its holdings in Obseva by 54.2% during the 3rd quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock worth $334,000 after purchasing an additional 14,100 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Obseva by 96.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,923 shares of the company’s stock worth $366,000 after purchasing an additional 47,012 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Obseva by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after purchasing an additional 5,600 shares during the last quarter. Institutional investors and hedge funds own 63.53% of the company’s stock.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit